Posts Feed
Comments Feed

« Couples Need Estimated Savings Of $225K To Cover Health Care Costs During Retirement, Study FindsIowa House Passes Bill That Would Provide Nearly All Uninsured Children With Health Coverage »

Astrazeneca Completes Enrolment In Second Pivotal Study For Vandetanib (Zactima (Tm) ) In Non-Small Cell Lung Cancer (NSCLC)

Mar 14th 2008Drug InformationLung Cancer

AstraZeneca announced that it has completed enrolment in a further two pivotal Phase III trials for investigational once-daily oral anti-cancer drug, vandetanib. Results from these two Phase III studies, ZODIAC and ZEAL, are expected later this year.

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

1